Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Ashish C. Bhatia MD, FAAD Associate Editor

Jane M. Grant-Kels MD, FAAD Advisory Board

Eliot N. Mostow MD, MPH Associate Editor

See All Experts

featured

Published in Dermatology

Journal Scan / Research · July 19, 2023

Characteristics and Management of Immune Checkpoint Inhibitor–Induced Pruritus

Photodermatology, Photoimmunology & Photomedicine

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Angad Chadha MD

Photodermatology, Photoimmunology & Photomedicine

A retrospective multicentric cohort study of checkpoint inhibitors-induced pruritus with focus on management

Photodermatol Photoimmunol Photomed 2023 Jun 12;[EPub Ahead of Print], C Papageorgiou, E Lazaridou, K Lallas, K Papaioannou, V Nikolaou, V Mateeva, K Efthymiadis, C Koukoutzeli, K Loga, E Sogka, E Karamitrousis, G Lazaridis, D Dionysopoulos, A Lallas, C Kemanetzi, C Fotiadou, E Timotheadou, Z Apalla

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Notice to Our Valued Users

Characteristics and Management of Immune Checkpoint Inhibitor–Induced Pruritus

Additional Info

A retrospective multicentric cohort study of checkpoint inhibitors-induced pruritus with focus on management

Further Reading

Final Note From the Dermatology Editors

Outcomes of Treatment With 5-Fluorouracil 5% Cream in Patients With Squamous Cell Carcinoma In Situ

Outcomes of Field-Directed Photodynamic Therapy Using BF-200 ALA in Patients With Actinic Keratosis

Patient Preferences Regarding the Treatment of Bowen's Disease

Cost-Utility Analysis of Clinic-Based Deroofing vs Local Excision for Hidradenitis Suppurativa

Assessing the Strategies Used to Improve Patient Diversity in a Novel Psoriasis Study

Clinical Presentation, Diagnosis, and Management of Drug Reaction With Eosinophilia and Systemic Symptoms

Association of Gabapentinoid Use With Risk of Hip Fracture

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Clinical Safety and Efficacy of Dual-Wavelength Low-Level Light Therapy Among Patients With Androgenetic Alopecia

Recently Updated